source
- US-China biotech rivalry sparks calls for deeper discussion, says editorThe editor notes that the ongoing debate over the competitive relationship between U.S. and Chinese biotechnology sectors has been unfolding over recent months. While many knowledgeable voices are…
- Amgen drops early-stage obesity drug candidate AMG-513Amgen announced it is discontinuing its early-stage obesity candidate AMG-513. The program was in Phase 1, but the company provided no details about the study or the reasons for the halt. A spokes…